MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the FDA has designated THIO for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback